2009Journal of VisionOpen access

The ArgusTM II retinal prosthesis restores some sight to the blind

Jessy D. Dorn

Open full text 0 citations

Abstract

The Argus™ II is the second generation of an electronic retinal implant designed for the treatment of progressive blindness due to inherited eye diseases that result in photoreceptor degeneration, such as Retinitis Pigmentosa (RP) and Macular Degeneration. The first generation Argus™ 16 prosthesis was implanted in six RP subjects between 2002 and 2004 and has enabled them to detect when lights are on or off and also to locate, differentiate, and describe the motion of basic objects in an environment. The Argus™ II implant consists of an array of 60 independently controllable electrodes that are attached to the retina. A microprocessor determines the stimulation current of each electrode based on the brightness at the corresponding area of the scene, which is captured in real-time by a miniature video camera mounted on a pair of sunglasses. The electrodes stimulate visual cells spared by the disease, creating spots of light and providing a rudimentary form of sight to implanted subjects. Second Sight® Medical Products, Inc. has enrolled subjects in the US, Mexico and Europe as part of a clinical study to examine the safety and effectiveness of the Argus™ II Retinal Prosthesis System. This talk will describe the underlying principles of the system, the current status of our clinical study, and the plans for future research and development of retinal prostheses.

About this research paper

What this paper is about

The Argus™ II is the second generation of an electronic retinal implant designed for the treatment of progressive blindness due to inherited eye diseases that result in photoreceptor degeneration, such as Retinitis Pigmentosa (RP) and Macular Degeneration. The first generation Argus™ 16 prosthesis was implanted in six RP subjects between 2002 and 2004 and has enabled them to detect when lights are on or off and also to locate, differentiate, and describe the motion of basic objects in an environment. The Argus™ II implant consists of an array of 60 independently controllable electrodes that are attached to the retina. A microprocessor determines the stimulation current of each electrode based on the brightness at the corresponding area of the scene, which is captured in real-time by a miniature video camera mounted on a pair of sunglasses. The electrodes stimulate visual cells spared by the disease, creating spots of light and providing a rudimentary form of sight to implanted subjects. Second Sight® Medical Products, Inc. has enrolled subjects in the US, Mexico and Europe as part of a clinical study to examine the safety and effectiveness of the Argus™ II Retinal Prosthesis System. This talk will describe the underlying principles of the system, the current status of our clinical study, and the plans for future research and development of retinal prostheses.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

The Argus™ II is the second generation of an electronic retinal implant designed for the treatment of progressive blindness due to inherited eye diseases that result in photoreceptor degeneration, such as Retinitis Pigmentosa (RP) and Macular Degeneration. The first generation Argus™ 16 prosthesis was implanted in six RP subjects between 2002 and 2004 and has enabled them to detect when lights are on or off and also to locate, differentiate, and describe the motion of basic objects in an environment. The Argus™ II implant consists of an array of 60 independently controllable electrodes that are attached to the retina. A microprocessor determines the stimulation current of each electrode based on the brightness at the corresponding area of the scene, which is captured in real-time by a miniature video camera mounted on a pair of sunglasses. The electrodes stimulate visual cells spared by the disease, creating spots of light and providing a rudimentary form of sight to implanted subjects. Second Sight® Medical Products, Inc. has enrolled subjects in the US, Mexico and Europe as part of a clinical study to examine the safety and effectiveness of the Argus™ II Retinal Prosthesis System. This talk will describe the underlying principles of the system, the current status of our clinical study, and the plans for future research and development of retinal prostheses.

Key concepts: Retinal implant, Visual prosthesis, Retinitis pigmentosa, Argus, Retinal Prosthesis, Sight, Implant, Retinal

Related papers

Back to paper searchBrowse research topicsOriginal source
The ArgusTM II retinal prosthesis restores some sight to the blind — Research Paper | ScholarLens